Abstract
Background and Purpose—
The
proportion of patients with acute ischemic stroke or transient ischemic
attack (TIA) and obesity who successfully achieve goals for weight
reduction recommended by major professional organizations is unknown.
Methods—
We
examined the experience of participants in the placebo group of the
IRIS trial (Insulin Resistance Intervention after Stroke) with a body
mass index ≥30 kg/m2 at entry. Patients were of age ≥40
years, with a qualifying stroke or TIA within 180 days of randomization
and documented insulin resistance without diabetes mellitus. Weights at
baseline and at years 1 and 2 after entry were analyzed to determine the
proportion of patients achieving a 5% weight loss and achievement of
body mass index <27 kg/m2.
Results—
Of
1937 subjects assigned to placebo, 855 (44%) had obesity at entry.
Median age of these 855 subjects was 60 years (interquartile range,
53–68), 41% were women, and median time from stroke/TIA to trial entry
was 79 days. Among 788 subjects in the trial at 1 year, 166 (21%) had
lost at least 5% of their starting weight and 12 (2%) had achieved a
body mass index <27 kg/m2. One hundred nine (14%)
participants gained at least 5% of their baseline weight at 1 year.
Among 744 subjects in the trial at 2 years, 185 (25%) had lost at least
5% of their baseline weight and 23 (3%) had achieved a body mass index
<27 kg/m2. One hundred forty (19%) participants gained at least 5% of their starting weight at 2 years.
Conclusions—
Only
one quarter of obese patients with a recent ischemic stroke or TIA lost
a clinically significant amount of weight after their vascular event.
Many patients gained weight. Enhancing weight loss after ischemic stroke
or TIA may help improve functional outcome and reduce risk for future
vascular events, but clinical trials are needed to test and confirm
these potential benefits.
Footnotes
No comments:
Post a Comment